Hiroshi Nokihara

10PUBLICATIONS
40CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersRadiation therapyGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Aug 01, 2024
Efficacy of first-line immune checkpoint inhibitor and anti-angiogenic agent combination therapy for Kirsten rat sarcoma viral antigen-mutant advanced non-small-cell lung cancer: a systematic review and network meta-analysis.

Akinari Tsukada, Chie Morita, Yosuke Shimizu

|Dec 26, 2023
Potential of fluoropyrimidine to be an immunologically optimal partner of immune checkpoint inhibitors through inducing immunogenic cell death for thoracic malignancies.

Hiroyuki Kozai, Hirokazu Ogino, Atsushi Mitsuhashi

|Dec 13, 2023
An increased relative eosinophil count as a predictive dynamic biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors.

Eiji Takeuchi, Hirokazu Ogino, Kensuke Kondo

|Sep 17, 2023
A multicenter, open-label, phase II trial of pemetrexed plus bevacizumab in elderly patients with previously untreated advanced or recurrent nonsquamous non-small cell lung cancer.

Yohei Yabuki, Masaki Hanibuchi, Eiji Takeuchi

|Sep 05, 2023
Pretreatment eosinophil counts as a predictive biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors.

Eiji Takeuchi, Kensuke Kondo, Yoshio Okano

|Sep 15, 2022
Efficacy and safety of second-line chemotherapy for patients with advanced non-small cell lung cancer complicated by interstitial lung disease.

Kenji Otsuka, Hiroshi Nokihara, Atsushi Mitsuhashi

Pageof 2

Frequent Collaborators

7 joint publications

Yasuhiko Nishioka

3 joint publications

Eiji Takeuchi

1 joint publications

Ryosuke Oki

1 joint publications

Yuishin Izumi